MORTIMER IAN — SEC Form 4 filings

SEC reporting owner CIK 1619961. 10 Form 4 filings on record with FilingPulse; latest filed 2026-03-13.

Transaction summary — filings shown

Covers all 10 filings on record, filed 2024-03-12 to 2026-03-13. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Xenon Pharmaceuticals Inc. (XENE)PRESIDENT & CEO, Director1022 legs · 433,879 sh · $23,512,05329

Form 4 filings — MORTIMER IAN

FiledFormIssuerReported transactionsSource
2026-03-134Xenon Pharmaceuticals Inc. (XENE)Option exercise (M): 12,500 · Sale (S): 7,308 @ $55.23 · Option exercise (M): 12,500 (derivative) @ $0EDGAR
2026-03-114Xenon Pharmaceuticals Inc. (XENE)Option exercise (M): 75,000 @ $8.40 · Sale (S): 21,791 @ $58.81 · Sale (S): 31,694 @ $59.88 · Sale (S): 21,515 @ $60.49 · Option exercise (M): 25,000 @ $3.10 · Sale (S): 12,479 @ $59.50 · +15 moreEDGAR
2026-01-094Xenon Pharmaceuticals Inc. (XENE)Grant/award (A): 350,000 (derivative) @ $0 · Grant/award (A): 65,000 (derivative) @ $0EDGAR
2026-01-024Xenon Pharmaceuticals Inc. (XENE)Option exercise (M): 40,000 @ $7.49 · Sale (S): 37,938 @ $44.40 · Sale (S): 2,062 @ $44.93 · Option exercise (M): 40,000 (derivative) @ $0EDGAR
2025-12-094Xenon Pharmaceuticals Inc. (XENE)Sale (S): 14,375 @ $45.03 · Sale (S): 8,820 @ $45.59 · Sale (S): 2,010 @ $46.32EDGAR
2025-12-034Xenon Pharmaceuticals Inc. (XENE)Sale (S): 97 @ $45.01EDGAR
2025-10-014Xenon Pharmaceuticals Inc. (XENE)Option exercise (M): 25,000 @ $7.69 · Sale (S): 25,000 @ $40.16 · Option exercise (M): 25,000 (derivative) @ $0EDGAR
2025-03-134Xenon Pharmaceuticals Inc. (XENE)Grant/award (A): 275,000 (derivative) @ $0 · Grant/award (A): 50,000 (derivative) @ $0EDGAR
2025-01-274Xenon Pharmaceuticals Inc. (XENE)Option exercise (M): 16,217 @ $17.76 · Sale (S): 16,217 @ $40.08 · Option exercise (M): 22,468 @ $17.76 · Sale (S): 22,468 @ $40.20 · Option exercise (M): 15,166 @ $17.76 · Sale (S): 15,166 @ $40.46 · +5 moreEDGAR
2024-03-124Xenon Pharmaceuticals Inc. (XENE)Grant/award (A): 250,000 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1619961 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →